Lumitron, the Israeli representative of Agilent Technologies, participated in a professional feature article discussing how advanced technologies help reduce risk and improve decision-making processes in drug development.
The article highlights the growing shift from basic measurement technologies to advanced tools, that provide more accurate insights into cellular activity during early research and development stages.
One of the leading technologies featured in the article is Spectral Flow Cytometry. This technology enables high-resolution multiparametric analysis of thousands of cells simultaneously and helps researchers identify subtle biological differences that were previously difficult to detect.
The article also presents Agilent Technologies’ NovoCyte Opteon systems. These advanced platforms provide high-resolution cellular analysis capabilities and help researchers and biotechnology companies gain more accurate insights into cellular responses to treatments, disease mechanisms, and the effectiveness of drug candidates during early development stages.
According to Nimrod Elbocher, CEO of Lumitron, more organizations now recognize the business and economic value of accurate cellular analysis. Improving data quality and enabling earlier decision-making helps achieve better results, shorten development timelines, and reduce repeated experiments.
Read the full article on Ynet Capital >>>